Highlights

Eye chip for the blind

mehr

New materials

mehr

Biochips for personalized medicine

Speedier test results, more details for test parameters and cost-effectiveness are of key importance in the development of drugs and future diagnostic procedures.


Ten years ago, NMI was one of the first institutes worldwide to publish its results of a study on a miniature protein biochip aimed at ascertaining autoimmune diseases. Through protein biochips, a number of biomarkers can be detected in a sensitive and selective manner even in a very small sample from a patient. These chips thus facilitate a more exact diagnosis which, in turn, is a prerequisite for an effective, individualized therapy with negligible side-effects.


In its effort to establish the feasibility of biochip technology, the NMI is working with world-renowned diagnostic and pharmaceutical companies.